Don't miss an issue! Renew/subscribe for FREE today.

Free Shipping from Ivoclar Vivadent's LabShop

Posted on Thursday, January 9, 2014

BIOMET 3i Announces Launch of New Slim Kit

Posted on Monday, January 6, 2014

Creodent Offers Direct Composite Course

Posted on Monday, January 6, 2014

Adults With Diabetes Need a Flu Shot: Experts

Posted on Friday, January 31, 2014

(HealthDay News) -- Adults with diabetes are vulnerable to flu and its complications, experts say. Now a large new study finds they're also at higher risk of being hospitalized for flu.

To read more of the HealthDay article, click here.

Water Fluoride Levels Do Not Increase Risk for Bone Cancer: Study

Posted on Friday, January 31, 2014

Fluoride levels in drinking water do not lead to a greater risk of primary bone cancer, a new study has found.

Researchers at Newcastle University found that higher levels of natural or artificial fluoride in drinking water in the UK had no impact on the incidence of either osteosarcoma or Ewing’s sarcoma in people aged 0-49.

The study, funded by charity Bone Cancer Research Trust (BCRT), analysed 2,566 osteosarcoma and 1,650 Ewing’s sarcoma cases during 1980 and 2005.

Artificial fluoridation of drinking water to improve dental health has long been a controversial topic, with opponents citing a possible link with increased risk of primary bone cancer.

Fluoride in drinking water 

Dr Richard McNally of the Institute of Health & Society at Newcastle University, who led the study, said: “This is the largest study that has ever been conducted examining the possible association between fluoride in drinking water and risk of osteosarcoma or Ewing sarcoma.

“Karen Blakey used sophisticated software to link together data on the geographical distributions of bone cancer incidence and fluoride levels. Statistical modelling of these data showed that there was no evidence of an association.”

Andy Hall, chairman of BCRT’s Independent Scientific Advisory Committee, welcomed the findings of the study.

“Bone cancer is diagnosed in about 550 patients every year in the UK and Ireland, many of whom are children. However, at present, very little is known of the factors which trigger the disease.

“The study funded by the Bone Cancer Research Trust and reported by the team in Newcastle provides very important reassurance to patients and their relatives that fluoride is not involved in this process and shows that more research is needed to find out how this potentially devastating form of cancer can be prevented.”

Reference: Is fluoride a risk factor for bone cancer? Small area analysis of osteosarcoma and Ewing sarcoma diagnosed among 0–49-year-olds in Great Britain, 1980–2005 International Journal of Epidemiology

Researchers Launch Phase 1 Clinical Trial of Potential MRSA Treatment

Posted on Thursday, January 30, 2014

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. The Phase 1 trial, which will enroll as many as 64 healthy men and women ages 18 to 45, will evaluate the investigational drug’s safety as well as how it is broken down and processed in the body. The trial is being conducted by the Massachusetts-based biotechnology company Enanta Pharmaceuticals through contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID funded Enanta’s earlier preclinical testing and development of EDP-788.


Infections with bacteria resistant to antibiotic drugs were first reported in the 1940s, with the earliest cases of MRSA appearing in the 1960s. Since then, MRSA and other antibiotic-resistant infections have become more common in both health care settings and the broader community. EDP-788 belongs to a novel class of antibiotics known as bicyclolides, which were designed to overcome resistance. In laboratory and small animal experiments, EDP-788 and other bicyclolides have demonstrated potent activity against a variety of infectious bacteria, including MRSA.


In the new trial, participants will receive either a single dose of EDP-788 in pill form or a placebo. Two weeks later, a subset of participants will receive a second dose or placebo—either in liquid form, to assess the effect of formulation on absorption into the body; or in pill form along with a meal, to assess the effect of food on absorption. Blood levels of the drug will be measured for three days after receiving each dose, and participants’ safety will be monitored for eight to ten days after each dose.

EPA Takes Important Step in Implementing the Hazardous Waste Electronic Manifest Establishment Act

Posted on Thursday, January 30, 2014

WASHINGTON - The U.S. Environmental Protection Agency (EPA) this month issued a final rule that is a crucial step in the development of a national electronic manifest (e-Manifest) system, which will upgrade the current paper-based system of tracking hazardous waste to an electronic one.

“Today’s action is a key step in bringing the oversight of these potentially dangerous materials into the 21st century,” said Mathy Stanislaus, EPA assistant administrator for the Office of Solid Waste and Emergency Response. “Once fully implemented, the national e-Manifest system will provide greater access for emergency responders to information about the types and sources of hazardous waste that are in transit between generator sites and waste management facilities.”

The final rule authorizes the use of e-Manifests to track hazardous wastes under the Resource Conservation and Recovery Act. This will allow the current process, which requires paper forms, to be streamlined and greatly reduce the millions of paper manifests produced each year.

The Hazardous Waste Electronic Manifest Establishment Act requires EPA to issue a regulation authorizing the use of electronic manifests as the legal equivalent of the current paper manifest forms used to track shipments of hazardous waste from a generator’s site to the ultimate site of disposal. EPA’s goal is to promote the greatest possible use of electronic manifests.

The e-Manifest program is the vanguard of the agency-wide initiative to develop new tools to reduce the reporting burden on regulated entities, and provide the agency, states and the public with easier access to environmental data. EPA estimates the national e-Manifest system will ultimately reduce the burden associated with preparing shipping manifests by between 300,000 and 700,000 hours, and result in cost savings of more than $75 million per year for states and industry. In line with the agency’s e-Enterprise principles, the e-Manifest system will significantly improve access to higher quality and more timely waste shipment data, and will empower communities through increased transparency and more accurate information on completed waste shipments and management trends.

The final rule will establish the legal and policy framework for using electronic manifests; however, several more steps will be needed before the e-Manifest program can be implemented. These include establishing the system and initial fee structure. This year, EPA will work with states, industry and other stakeholders to develop plans for the many key aspects of the system and address concerns of intersystem compatibility. The Agency will also begin developing the initial fee structure of the system, including implementation and compliance dates, through a rulemaking. Stakeholders and interested parties will have the opportunity to comment on the proposed rule when it becomes available.

For more information:

Dental Insurance Doesn't Guarantee People Will Care for Their Teeth

Posted on Wednesday, January 29, 2014

(HealthDay News) -- Having dental insurance doesn't mean people will actually take care of their teeth, a new study indicates.

To read more of the HealthDay News study, click here.

© 2024 Conexiant | Privacy Policy